company background image
ENZ

Enzo BiochemNYSE:ENZ Stock Report

Last Price

US$3.20

Market Cap

US$155.1m

7D

-1.5%

1Y

7.0%

Updated

20 Jan, 2022

Data

Company Financials
ENZ fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends0/6

ENZ Stock Overview

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.

Enzo Biochem Competitors

Laboratory Corporation of America Holdings

NYSE:LH

US$26.0b

Quest Diagnostics

NYSE:DGX

US$17.0b

Thermo Fisher Scientific

NYSE:TMO

US$231.8b

Abcam

AIM:ABC

UK£3.0b

Price History & Performance

Summary of all time highs, changes and price drops for Enzo Biochem
Historical stock prices
Current Share PriceUS$3.20
52 Week HighUS$4.85
52 Week LowUS$2.61
Beta0.82
1 Month Change0.63%
3 Month Change-3.32%
1 Year Change7.02%
3 Year Change-13.51%
5 Year Change-51.88%
Change since IPO16.20%

Recent News & Updates

Dec 17
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

ENZUS HealthcareUS Market
7D-1.5%-2.1%-4.0%
1Y7.0%12.8%6.6%

Return vs Industry: ENZ underperformed the US Healthcare industry which returned 12.7% over the past year.

Return vs Market: ENZ matched the US Market which returned 7.7% over the past year.

Price Volatility

Is ENZ's price volatile compared to industry and market?
ENZ volatility
ENZ Average Weekly Movement5.0%
Healthcare Industry Average Movement8.0%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: ENZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ENZ's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976483Hamid Erfanianhttps://www.enzo.com

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.

Enzo Biochem Fundamentals Summary

How do Enzo Biochem's earnings and revenue compare to its market cap?
ENZ fundamental statistics
Market CapUS$155.11m
Earnings (TTM)US$5.26m
Revenue (TTM)US$115.60m

29.5x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENZ income statement (TTM)
RevenueUS$115.60m
Cost of RevenueUS$62.67m
Gross ProfitUS$52.93m
ExpensesUS$47.67m
EarningsUS$5.26m

Last Reported Earnings

Oct 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin45.79%
Net Profit Margin4.55%
Debt/Equity Ratio6.7%

How did ENZ perform over the long term?

See historical performance and comparison

Valuation

Is Enzo Biochem undervalued compared to its fair value and its price relative to the market?

29.51x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENZ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENZ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENZ is poor value based on its PE Ratio (29.5x) compared to the US Healthcare industry average (20.5x).

PE vs Market: ENZ is poor value based on its PE Ratio (29.5x) compared to the US market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENZ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENZ is good value based on its PB Ratio (2.3x) compared to the US Healthcare industry average (2.6x).


Future Growth

How is Enzo Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzo Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Enzo Biochem performed over the past 5 years?

-44.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENZ has a high level of non-cash earnings.

Growing Profit Margin: ENZ became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ENZ's earnings have declined by 44.7% per year over the past 5 years.

Accelerating Growth: ENZ has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ENZ has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).


Return on Equity

High ROE: ENZ's Return on Equity (7.9%) is considered low.


Financial Health

How is Enzo Biochem's financial position?


Financial Position Analysis

Short Term Liabilities: ENZ's short term assets ($65.9M) exceed its short term liabilities ($23.1M).

Long Term Liabilities: ENZ's short term assets ($65.9M) exceed its long term liabilities ($18.3M).


Debt to Equity History and Analysis

Debt Level: ENZ has more cash than its total debt.

Reducing Debt: ENZ's debt to equity ratio has increased from 2.6% to 6.7% over the past 5 years.

Debt Coverage: ENZ's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if ENZ's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Enzo Biochem current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Hamid Erfanian (51 yo)

0.17

Tenure

Mr. Hamid Erfanian serves as Chief Executive Officer at Enzo Biochem, Inc. since November 8, 2021 and serves as Director since January 03, 2022. He served as Member of Executive Board at EUROIMMUN Medizini...


Leadership Team

Experienced Management: ENZ's management team is seasoned and experienced (8 years average tenure).


Board Members

Experienced Board: ENZ's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ENZ insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Enzo Biochem, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Enzo Biochem, Inc.
  • Ticker: ENZ
  • Exchange: NYSE
  • Founded: 1976
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$155.110m
  • Shares outstanding: 48.47m
  • Website: https://www.enzo.com

Number of Employees


Location

  • Enzo Biochem, Inc.
  • 527 Madison Avenue
  • New York
  • New York
  • 10022
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/20 23:53
End of Day Share Price2022/01/20 00:00
Earnings2021/10/31
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.